Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold higher than CDK1, CDK2 (IC50 is 578 nM), CDK5 and CDK9 respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride has anti-tumor effects.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 117.00 | |
2 mg | In stock | $ 165.00 | |
5 mg | In stock | $ 249.00 | |
10 mg | In stock | $ 397.00 | |
25 mg | In stock | $ 662.00 | |
50 mg | In stock | $ 942.00 | |
100 mg | In stock | $ 1,280.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 273.00 |
Description | Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold higher than CDK1, CDK2 (IC50 is 578 nM), CDK5 and CDK9 respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride has anti-tumor effects. |
Targets&IC50 | CDK6-CyclinD1:34 μM, CDK4-CyclinD1:49 μM, CDK9-CyclinT1:1.2 μM, CDK7-CyclinH:41 nM, CDK2-CyclinA:578 nM, CDK5-p35 NCK:9.4 μM, CDK1-CyclinA:1.8 μM |
In vitro | Samuraciclib (ICEC0942; 0-10 μM; 24 hours; HCT116 cells) treatment can promote apoptosis. Samuraciclib (ICEC0942; 0-10 μM; 24 hours; HCT116 cells) treatment can induce cell cycle arrest. Samuraciclib (ICEC0942; 0-10 μM; 0-24 hours; HCT116 cells) treatment inhibited the phosphorylation of PolII CTD in HCT116 colon cancer cells in a dose- and time-dependent manner. ICEC0942 also inhibits the phosphorylation of CDK1, CDK2 and retinoblastoma. Samuraciclib (ICEC0942) inhibits the growth of MCF7, T47D, MDA-MB-231, HS578T, MDA-MB-468, MCF10A and HMEC cells with GI50 values of 0.18 μM, 0.32 μM, 0.33 μM, 0.21 μM, 0.22 μM It is 0.67 μM and 1.25 μM. |
In vivo | Samuraciclib (ICEC0942; 100 mg / kg; oral tube; daily; 14 consecutive days; female nu / nu-BALB / c athymic nude mice) treatment inhibited tumor growth by 60% on day 14 with a significant reduction in PolII Ser2 and Ser5 phosphorylation in PBMC and tumors. The combination of Samuraciclib (ICEC0942) and ICI 47699 treatment showed complete stagnation of estrogen receptor (ER) positive tumor xenografts. |
Synonyms | ICEC0942 hydrochloride, CT7001 hydrochloride |
Molecular Weight | 430.97 |
Formula | C22H31ClN6O |
CAS No. | 1805789-54-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 55 mg/mL (127.62 mM), Sonication is recommended.
DMSO: 25 mg/mL (58.01 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Samuraciclib hydrochloride 1805789-54-1 Apoptosis Cell Cycle/Checkpoint CDK CT 7001 ICEC0942 hydrochloride CT7001 hydrochloride ATP-competitive Samuraciclib inhibit deregulation Inhibitor CT7001 non-covalent phosphorylates CT-7001 Hydrochloride ICEC-0942 anti-tumor CT 7001 Hydrochloride Samuraciclib Hydrochloride CT7001 Hydrochloride CT-7001 ICEC0942 Hydrochloride ICEC 0942 Hydrochloride Asp155 ICEC-0942 Hydrochloride cycle CDK7 ICEC 0942 arrest ICEC0942 PolII Cyclin dependent kinase inhibitor